LifeWallet Reveals $3.1M Settlement In Latest Pharmaceutical Antitrust Case
LifeWallet Reveals $3.1M Settlement In Latest Pharmaceutical Antitrust Case
LifeWallet公佈最新藥品反壟斷案件的310萬美元和解協議。
- Company also announces a drive to secure agreements with health plans, property & casualty insurers, attorneys, and healthcare providers, including hospital systems
- This subscription licensing is expected to generate revenue through fees charged on savings from unnecessary Medicare secondary payments
- This is all part of LifeWallet's clearinghouse system, through its exclusive healthcare partnership with Palantir Technologies, Inc.
- 公司還宣佈了與健康計劃、財產和意外傷害保險公司、律師和醫療保健提供商(包括醫院系統)達成協議的努力。
- 這種訂閱許可預計通過收取從不必要的醫療保險次要支付中省下的費用來生成收入。
- 這都是LifeWallet的清算系統的一部分，通過其與Palantir Technologies，Inc的獨家醫療保健合作伙伴關係實現的。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。